FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group

(2011) Uwe Pelzer et al.   EUROPEAN JOURNAL OF CANCER

FOLFIRINOX: A Small Step or a Great Leap Forward?

(2011) Andrew H. Ko   JOURNAL OF CLINICAL ONCOLOGY

Irinotecan Plus Bolus/Infusional 5-Fluorouracil and Leucovorin in Patients With Pretreated Advanced Pancreatic Carcinoma

(2010) Vittorio Gebbia et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer

(2009) C Yoo et al.   BRITISH JOURNAL OF CANCER

Second-line therapy for advanced pancreatic cancer: A review of the literature and future directions

(2009) Ana Custodio et al.   CANCER TREATMENT REVIEWS

Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

(2009) David Cunningham et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer

(2008) Henry Q. Xiong et al.   CANCER

Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer

(2008) Seong Yoon Yi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer

(2008) Stefan Boeck et al.   Future Oncology